Oct 12, 2023

Oct 12, 2023

Oct 12, 2023

Precision in Drug Discovery & Preclinical Summit 2023

Advancing Innovation at Preclinical Summit

On October 12-13, 2023, Model Medicines participated in the Precision in Drug Discovery & Preclinical (PDDP) Summit held in San Diego, CA.

The PDDP event convenes leading researchers and executives from across biopharma, academia, biotech, and more to connect on the latest R&D strategies and technologies powering cutting-edge drug discovery.

As pioneers in AI-driven drug development, Model Medicines attended to:

  • Share our advances leveraging scalable data and multi-modal AI to reimagine R&D

  • Highlight innovations like our Constellation technique and generative chemistry concepts

  • Discuss collaborative opportunities to translate biological complexity into better medicines

  • Interact with fellow innovators to collectively elevate the process of therapeutic invention

We appreciated the insightful dialogue and chance to exchange ideas on overcoming key industry challenges. Events like PDDP play a valuable role in advancing preclinical technologies for the benefit of patients worldwide.

Learn More

To learn more about Model Medicines’ differentiated platform and collaborative programs, visit www.modelmedicines.com/investors or reach out to us.

Details

Date

Oct 12, 2023

Category

Events

Reading

1 Min

Author

Patrick ONeill

Investor Relations

Related News

Jan 21, 2025

Announcement

Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral

Jan 21, 2025

Announcement

Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral

Jan 21, 2025

Announcement

Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral

Jan 14, 2025

Pre-Print

MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases

Jan 14, 2025

Pre-Print

MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases

Jan 14, 2025

Pre-Print

MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases